Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced positive 30-day results from the first 101 patients enrolled in the second phase of the ABSORB trial. Patients treated with Abbott's bioresorbable vascular scaffold (BVS), under clinical investigation in Europe, demonstrated no cases of blood clots (thrombosis), no need for repeat procedures
Pfizer Discontinues A Phase 3 Study Of Figitumumab
- Details
- Category: Pfizer
Pfizer Inc. announced the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).
Sanofi-aventis Successfully Completes the Acquisition of Chattem, Inc.
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has completed its acquisition of 100% of Chattem, Inc., which is now a wholly-owned subsidiary of the sanofi-aventis Group.
Roche and Biogen Idec decide to suspend Ocrelizumab treatment
- Details
- Category: Roche
Roche and Biogen Idec announced their decision to suspend Ocrelizumab treatment of patients in the Rheumatoid Arthritis (RA) programme. The decision follows the recommendation of the independent Ocrelizumab RA & Lupus Data and Safety Monitoring Board (DSMB) based on their assessment of the studies in RA (SCRIPT, FEATURE, FILM and STAGE) and lupus (BELONG and BEGIN).
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
- Details
- Category: Abbott
Abbott (NYSE: ABT) and Facet Biotech Corporation (Nasdaq: FACT) announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.
Novel Drug for Chronic Management of Hyperuricemia in Gout Patients
- Details
- Category: Product
Teijin Pharma Limited announced the European launch of TMX-67 (febuxostat), a novel drug discovered by Teijin Pharma for the treatment of hyperuricemia in patients with gout. Ipsen, a global biotechnology specialty care group and the TMX-67 licensee in Europe, and its sublicensee the Menarini Group, the first Italian pharmaceutical group in the world, have began marketing the product in Europe under the brand name ADENURIC(r).
Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.
More Pharma News ...
- Lundbeck delivers 22 percent revenue growth for 2009
- Bristol-Myers Squibb and Allergan Enter Global Agreement
- Anavex comments on failure of Pfizer and Medivation's Alzheimer's Investigational drug Dimebon
- Pfizer and Medivation Announce Results From Two Phase 3 Studies in Dimebon
- Novo Nordisk receives FDA approval for Norditropin® FlexPro® for growth hormone treatment
- FDA Advisory Committee Recommends Approval of Belatacept
- Initiation of Phase 2 Clinical Trial Investigating Three Individual HCV Antivirals